Advagene Biopharma Co (ROCO:6709) EBIT: NT$-68.11 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6709 Advagene Biopharma Co Ltd ROCO:6709
36 GF Score
Price NT$24.55
! 2 Warning Signs
View Full Analysis

What is Advagene Biopharma Co EBIT?

Advagene Biopharma Co ROCO:6709 +0.41% 36 EBIT is NT$-68.11 Mil as of Dec. 2025. GuruFocus rates ROCO:6709 with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

Advagene Biopharma Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was NT$-35.12 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-68.11 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Advagene Biopharma Co's annualized ROC % for the quarter that ended in Dec. 2025 was -301.34%. Advagene Biopharma Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -297.09%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Advagene Biopharma Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -4.33%.

Advagene Biopharma Co  (ROCO:6709) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Advagene Biopharma Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-72.752 * ( 1 - 0% )/( (25.441 + 22.844)/ 2 )
=-72.752/24.1425
=-301.34 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=197.256 - 4.131 - ( 167.684 - max(0, 6.189 - 190.829+167.684))
=25.441

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=166.513 - 8.836 - ( 134.833 - max(0, 11.613 - 159.012+134.833))
=22.844

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Advagene Biopharma Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-70.246/( ( (5.929 + max(19.014, 0)) + (7.003 + max(15.343, 0)) )/ 2 )
=-70.246/( ( 24.943 + 22.346 )/ 2 )
=-70.246/23.6445
=-297.09 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 23.145) - (4.131 + 0 + 0)
=19.014

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 24.179) - (8.836 + 0 + 0)
=15.343

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Advagene Biopharma Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-68.114/1573.871
=-4.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advagene Biopharma Co EBIT Related Terms

Advagene Biopharma Co EBIT Historical Data

* Premium members only.

The historical data trend for Advagene Biopharma Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advagene Biopharma Co EBIT Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -92.56 -118.30 -92.07 -69.27 -68.11

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.47 -31.37 -37.90 -32.99 -35.12

ROCO:6709 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Advagene Biopharma Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advagene Biopharma Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advagene Biopharma Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Advagene Biopharma Co's EV-to-EBIT falls into.


ROCO:6709
36GF Score
Advagene Biopharma Co Ltd ROCO:6709
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Advagene Biopharma Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-68.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-68.11 Mil mean?
Advagene Biopharma Co (ROCO:6709) has a EBIT of NT$-68.11 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Advagene Biopharma Co.
Is Advagene Biopharma Co's EBIT too high?
Advagene Biopharma Co's current EBIT is NT$-68.11 Mil. Overall, Advagene Biopharma Co has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Advagene Biopharma Co's EBIT compare to VRTX and REGN?
Advagene Biopharma Co's EBIT of NT$-68.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Advagene Biopharma Co. Advagene Biopharma Co's current EBIT is NT$-68.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advagene Biopharma Co stock overvalued right now?
Advagene Biopharma Co (ROCO:6709) has a current EBIT of NT$-68.11 Mil. The current EBIT is NT$-68.11 Mil. Advagene Biopharma Co's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Advagene Biopharma Co (ROCO:6709), the current EBIT is NT$-68.11 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advagene Biopharma Co Business Description

Address Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based biotechnology company. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray seasonal flu vaccine, nasal spray COVID-19 vaccine, Immunotherapy for COVID-19, Respiratory Allergy Immunotherapy - Allergic Rhinitis and Asthma ,and other vaccines.
36GF Score

Get the complete analysis for ROCO:6709

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.55
Price